참고문헌

EMEA. 2016a. Guideline on the Qualification and Reporting of Physiologically Based Pharmacokinetic (Pbpk) Modelling and Simulation. Vienna, Austria: EMEA. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500211315.pdf.

———. 2016b. Reflection Paper on Extrapolation of Efficacy and Safety in Paediatric Medicine Development. Vienna, Austria: EMEA. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/04/WC500204187.pdf.

FDA. 2009. Guidance for Industry End-of-Phase 2A Meetings. Maryland, US: U.S. Department of Health; Human Services Food; Drug Administration. https://www.fda.gov/downloads/Drugs/.../Guidances/ucm079690.pdf.

———. 2014. Guidance for Industry: General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products. Maryland, US: U.S. Department of Health; Human Services Food; Drug Administration.

ICH. 1993. International Conference on Harmonisation (Ich) Guidance: E7 Studies in Support of Special Populations: Geriatrics. Vienna, Austria: International Conference on Harmonisation.

———. 1994. International Conference on Harmonisation (Ich) Guidance: E4 Dose-Response Information to Support Drug Registration. Vienna, Austria: International Conference on Harmonisation.

Ke, A. B., S. C. Nallani, P. Zhao, A. Rostami-Hodjegan, N. Isoherranen, and J. D. Unadkat. 2013. “A Physiologically Based Pharmacokinetic Model to Predict Disposition of CYP2D6 and CYP1A2 Metabolized Drugs in Pregnant Women.” Drug Metabolism and Disposition 41 (4): 801–13. https://doi.org/10.1124/dmd.112.050161.

Ke, A B, S C Nallani, P Zhao, A Rostami-Hodjegan, and J D Unadkat. 2012. “A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction.” CPT: Pharmacometrics & Systems Pharmacology 1 (9): e3. https://doi.org/10.1038/psp.2012.2.

Leong, R, M L T Vieira, P Zhao, Y Mulugeta, C S Lee, S-M Huang, and G J Burckart. 2012. “Regulatory Experience with Physiologically Based Pharmacokinetic Modeling for Pediatric Drug Trials.” Clinical Pharmacology & Therapeutics 91 (5): 926–31. https://doi.org/10.1038/clpt.2012.19.

Mehrotra, N., A. Bhattaram, J. C. Earp, J. Florian, K. Krudys, J. E. Lee, J. Y. Lee, et al. 2016. “Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.” Drug Metabolism and Disposition 44 (7): 924–33. https://doi.org/10.1124/dmd.116.069559.

Sato, M, Y Ochiai, S Kijima, N Nagai, Y Ando, M Shikano, and Y Nomura. 2017. “Quantitative Modeling and Simulation in PMDA: A Japanese Regulatory Perspective.” CPT: Pharmacometrics & Systems Pharmacology 6 (7): 413–15. https://doi.org/10.1002/psp4.12203.

Zhao, Liang. 2016. Mechanistic Oral Absorption Modeling and Simulation for Formulation Development and Bioequivalence Evaluation; Public Workshop. U.S. Department of Health; Human Services Food; Drug Administration. https://www.fda.gov/downloads/Drugs/NewsEvents/UCM505000.pdf.

의약품심사부 종양약품과. 2015. 의약품 개발 시 집단 약동학 활용을 위한 가이드라인. 대한민국: 식품의약품안전평가원. https://www.nifds.go.kr/brd/m_15/view.do?seq=7038.